Proven safe and effective
The INTERCEPT Blood System for platelets provides robust, broad-spectrum inactivation, reducing the risks of TTI, including sepsis. In addition, the number of T-cells is reduced to a level that potentially reduces the risk of transfusion-associated graft-versus-host disease (TA-GVHD). The safety and efficacy of INTERCEPT Blood System processed platelets (“INTERCEPT Platelets”) has been supported by hemovigilance programs and several clinical trials.
INTERCEPT Platelets
Demonstrated prevention of septic reactions in routine use
Hemovigilance (HV) programs provide a comprehensive view of transfusions and potential adverse events via the surveillance of blood donations in routine use settings. Over 700,000 INTERCEPT Blood System processed platelet units have been transfused in French, Swiss and Belgian national HV programs, with no reported transfusion-transmitted infections or sepsis-related fatalities to-date.1
| Conventional Platelets | INTERCEPT Platelets | |||
| HV Program |
Platelet Units Transfused (n) |
Transfusion Transmitted Infections (Fatalities) |
Platelet Units Transfused (n) |
Transfusion Transmitted Infections |
| France1,2 2006-2016 |
2,860,529 | 51 (9) | 236,099 | 0 |
| Switzerland3,13 2005-2017 |
156,719 | 16 (3) | 243,100 | 0 |
| Belgium12 2009-2015 |
294,477 | 9 (0) | 226,378 | 0 |
| Total | 3,311,725 | 76 (12) | 705,577 | 0 |
Clinical trials
The INTERCEPT Blood System has been evaluated in numerous clinical trials comprised of over 1000 subjects that received INTERCEPT Platelets. Primary endpoints were met in the controlled, randomized clinical trials, including corrected count increments (CCI) and bleeding criteria, both of which are measures of hemostatic efficacy. The frequency of acute transfusion reactions (ATRs) was assessed in three observational studies.
| Study Description | Patients | Design | Primary Endpoint | Primary Endpoint Met? |
| Viability of INTERCEPT Platelets, clearance of amotosalen, healthy patients4,5 | 65 | Randomized, single-blind, cross-over | Recovery/survival, clearance of amotosalen |  |
| Safety/efficacy of INTERCEPT Platelets, thrombocytopenic patients6 | 645 | Randomized, double-blind, parallel | WHO Grade 2 bleeding | |
| Safety/efficacy of INTERCEPT Platelets, thrombocytopenic patients7 | 43 | Randomized, double-blind, parallel | 1 hour CCI | |
| Safety/efficacy of INTERCEPT Platelets, thrombocytopenic patients8 | 32 | Randomized, double-blind, cross-over | Bleeding time | |
| Safety of INTERCEPT Routine setting9 | 51 | Single-arm, open label | Frequency of acute transfusion reactions was 1.6% |
|
| Safety of INTERCEPT Routine setting10 | 46 | Single-arm, open label | Frequency of acute transfusion reactions was 2% |
|
| Safety of INTERCEPT Routine setting11 | 169 | Single-arm, open label | Frequency of acute transfusion reactions was 2.4% |
|
References
- Sweeney J et al. Platelet Transfusion Therapy. Bethesda: AABB Press, 2013
- Agence Francaise de Securite Sanitaire des Produits de Sante, Rapport Annuel Hemovigilance 2009-2016.
- Swissmedic, Haemovigilance Annual Report, 2005-2017.
- Snyder E et al. Transfusion 2004;44:1732-1740.
- Corash L et al. Transfusion 2000;40(S10):137.
- McCullough et al. Blood 2004;104(5):1534-1541.
- Janetzko et al. Transfusion 2005;45:1443-1452.
- Slichter SJ et al. Transfusion 2006;46:731-740.
- Schlenke P et al. Ann Hematol 2011;90(12):1457-1465.
- Infanti L et al. Transfus Apher Sci 2011;45(2):175-181.
- The INTERCEPT Blood System for Platelets - Dual Storage Set Package Insert, March 15, 2016
- Benjamin et al. Transfusion 2017;57:2946-5
- Jutzi M. et al. Transfus Med Hemother 2018;45:151-6.